Li Han
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Li Han has a total of 103 co-authors. Here are the top co-authors by number of shared publications:
- Jianjun Chen
Department of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, USA
5 shared publications - Lu Yang
Department of Systems Biology, Beckman Research Institute of the City of Hope, Duarte, USA
5 shared publications - Bin Zhang
Gehr Family Center for Leukemia Research, Hematology Malignancies and Stem Cell Transplantation Institute, City of Hope Medical Center, Duarte, USA
4 shared publications - Chao Shen
Department of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA 91016, USA
4 shared publications - Chengwan Zhang
Department of Central Laboratory, The Affiliated Huaian No. 1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu 223300, P.R. China
4 shared publications - Chuan He
Department of Chemistry, University of Chicago, Chicago, USA
4 shared publications
Latest Publications
- 14 April 2026
- Published by Springer Nature in Oncogene
- Vol. 45 (20) , 1914-1929
Blocking ubiquitination of hnRNPA1 maintains the self-renewal of breast cancer stem cells via mutually exclusive splicing of PKM pre-mRNA
PKM serves as a rate-limiting enzyme in glycolysis, which produces two isoforms depending on the inclusion of either exon 9 (PKM1) or exon 10 (PKM2). The M2 pyruvate kinase (PKM2) isoform is commonly upregulated in various cancers, where it plays a pivotal role in regulating Warburg effect. Breast cancer stem cells (BCSCs) exhibit enhanced glycolysis, which is crucial for their self-renewal. However, the specific role of PKM2 in BCSCs remains largely unexplored. Here, we report that PKM2 expression is upregulated in BCSCs. Meanwhile, we identify that LINC00887 is significantly upregulated in BRCA through a genome-wide LNCRNA microarray. Moreover, we recognize that hnRNPA1 interacts with PKM pre-mRNA and regulates its mutually exclusive splicing. Furthermore, we demonstrate that LINC00887 maintains the self-renewal of BCSCs by promoting PKM2 splicing and reprogramming glucose metabolism. Mechanistically, LINC00887 upregulates PKM2 expression by binding hnRNPA1, thereby concealing its ubiquitination site, which blocks its ubiquitination and maintains its stability. Consistently, overexpression of hnRNPA1 almost completely rescues/reverses the inhibitory effects of LINC00887 KD in BRCA. Collectively, our study characterizes the LINC00887/hnRNPA1/PKM1/2 axis in BRCA and reveals the essential role of LINC00887 in BCSCs self-renewal/maintenance through promoting hnRNPA1-mediated PKM2 splicing, highlighting the therapeutic potential of targeting cancer metabolism.
- 14 April 2026
- Published by Springer Nature in Oncogene
- Vol. 45 (20) , 1914-1929
Blocking ubiquitination of hnRNPA1 maintains the self-renewal of breast cancer stem cells via mutually exclusive splicing of PKM pre-mRNA
PKM serves as a rate-limiting enzyme in glycolysis, which produces two isoforms depending on the inclusion of either exon 9 (PKM1) or exon 10 (PKM2). The M2 pyruvate kinase (PKM2) isoform is commonly upregulated in various cancers, where it plays a pivotal role in regulating Warburg effect. Breast cancer stem cells (BCSCs) exhibit enhanced glycolysis, which is crucial for their self-renewal. However, the specific role of PKM2 in BCSCs remains largely unexplored. Here, we report that PKM2 expression is upregulated in BCSCs. Meanwhile, we identify that LINC00887 is significantly upregulated in BRCA through a genome-wide LNCRNA microarray. Moreover, we recognize that hnRNPA1 interacts with PKM pre-mRNA and regulates its mutually exclusive splicing. Furthermore, we demonstrate that LINC00887 maintains the self-renewal of BCSCs by promoting PKM2 splicing and reprogramming glucose metabolism. Mechanistically, LINC00887 upregulates PKM2 expression by binding hnRNPA1, thereby concealing its ubiquitination site, which blocks its ubiquitination and maintains its stability. Consistently, overexpression of hnRNPA1 almost completely rescues/reverses the inhibitory effects of LINC00887 KD in BRCA. Collectively, our study characterizes the LINC00887/hnRNPA1/PKM1/2 axis in BRCA and reveals the essential role of LINC00887 in BCSCs self-renewal/maintenance through promoting hnRNPA1-mediated PKM2 splicing, highlighting the therapeutic potential of targeting cancer metabolism.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S3 from ALKBH1 Drives Tumorigenesis and Drug Resistance via tRNA-decoding Reprogramming and Codon-biased Translation
Supplementary Table S1: Effects of ALKBH1 KD on f5C34 in mitochondrial tRNA-Met Supplementary Table S2: Genetic background of the AML patient samples. Supplementary Table S3: List of oligonucleotide sequences
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S3 from ALKBH1 Drives Tumorigenesis and Drug Resistance via tRNA-decoding Reprogramming and Codon-biased Translation
Supplementary Table S1: Effects of ALKBH1 KD on f5C34 in mitochondrial tRNA-Met Supplementary Table S2: Genetic background of the AML patient samples. Supplementary Table S3: List of oligonucleotide sequences
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Proteomics Data 1 from ALKBH1 Drives Tumorigenesis and Drug Resistance via tRNA-decoding Reprogramming and Codon-biased Translation
Quantitative proteomics after ALKBH1 knockdown in MOLM13 cells.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Proteomics Data 1 from ALKBH1 Drives Tumorigenesis and Drug Resistance via tRNA-decoding Reprogramming and Codon-biased Translation
Quantitative proteomics after ALKBH1 knockdown in MOLM13 cells.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S7 from ALKBH1 Drives Tumorigenesis and Drug Resistance via tRNA-decoding Reprogramming and Codon-biased Translation
Supplementary Figure S1. ALKBH1 is required for human AML cell survival/growth in vitro and human AML progression in vivo. Supplementary Figure S2. ALKBH1 is required for leukemic cell transformation, LSC/LIC self-renewal and AML maintenance. Supplementary Figure S3. ALKBH1 is dispensable for normal hematopoiesis. Supplementary Figure S4. ALKBH1 is required for mitochondrial functions in AML cells. Supplementary Figure S5. ALKBH1 specifically catalyzes the conversion of m5C/m5Cm to f5C in tRNAs and is crutial for protein translation in AML. Supplementary Figure S6. WDR43 is a direct target of ALKBH1 through tRNA f5C-mediaed codon biased translation and phenocopies the functions of ALKBH1 in AML. Supplementary Figure S7. Discovery of the ALKBH1/WDR43/BCL2 axis and the synergistic effect of targeting ALKBH1/WDR43/BCL2 axis together with venetoclax in treating AML.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S7 from ALKBH1 Drives Tumorigenesis and Drug Resistance via tRNA-decoding Reprogramming and Codon-biased Translation
Supplementary Figure S1. ALKBH1 is required for human AML cell survival/growth in vitro and human AML progression in vivo. Supplementary Figure S2. ALKBH1 is required for leukemic cell transformation, LSC/LIC self-renewal and AML maintenance. Supplementary Figure S3. ALKBH1 is dispensable for normal hematopoiesis. Supplementary Figure S4. ALKBH1 is required for mitochondrial functions in AML cells. Supplementary Figure S5. ALKBH1 specifically catalyzes the conversion of m5C/m5Cm to f5C in tRNAs and is crutial for protein translation in AML. Supplementary Figure S6. WDR43 is a direct target of ALKBH1 through tRNA f5C-mediaed codon biased translation and phenocopies the functions of ALKBH1 in AML. Supplementary Figure S7. Discovery of the ALKBH1/WDR43/BCL2 axis and the synergistic effect of targeting ALKBH1/WDR43/BCL2 axis together with venetoclax in treating AML.
- 4 August 2025
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 15 (11) , 2298-2325
ALKBH1 Drives Tumorigenesis and Drug Resistance via tRNA-decoding Reprogramming and Codon-biased Translation
Cancer cells utilize codon-biased translation to fuel tumorigenesis and drug resistance; however, underlying mechanisms remain poorly understood. In this study, we show that ALKBH1 is overexpressed in acute myeloid leukemia (AML) and essential for leukemia stem cell/leukemia-initiating cell self-renewal and AML development/maintenance but dispensable for normal hematopoiesis. ALKBH1 enhances mitochondrial assembly/function and oxidative phosphorylation, crucial for AML survival/proliferation and resistance to venetoclax, a potent BCL2 inhibitor and widely used first-line targeted therapy for AML in the clinic. Mechanistically, ALKBH1 catalyzes 5-formylcytosine at tRNA wobble positions, reprograming decoding and facilitating codon-biased translation, a mechanism we term “epitranslatomic Midas touch,” which in turn drives leukemogenesis and drug resistance by promoting the synthesis of key oncogenic proteins like WDR43. Targeting ALKBH1, particularly together with venetoclax, exhibited potent antileukemia efficacy in preclinical models with favorable safety profiles. Collectively, our findings elucidate ALKBH1’s pivotal role in codon-biased translation and tumorigenesis and propose a novel therapeutic strategy for cancer treatment. Significance: This study uncovers that ALKBH1-driven tRNA-decoding reprogramming and codon-biased translation, termed “epitranslatomic Midas touch,” is crucial for leukemogenesis, leukemia stem cell/leukemia-initiating cell self-renewal, mitochondria structure/function, and resistance to venetoclax. Targeting ALKBH1, especially in combination with venetoclax, offers a promising therapeutic strategy to combat drug resistance in AML and potentially other ALKBH1-overexpressing cancers.
- 4 August 2025
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 15 (11) , 2298-2325
ALKBH1 Drives Tumorigenesis and Drug Resistance via tRNA-decoding Reprogramming and Codon-biased Translation
Cancer cells utilize codon-biased translation to fuel tumorigenesis and drug resistance; however, underlying mechanisms remain poorly understood. In this study, we show that ALKBH1 is overexpressed in acute myeloid leukemia (AML) and essential for leukemia stem cell/leukemia-initiating cell self-renewal and AML development/maintenance but dispensable for normal hematopoiesis. ALKBH1 enhances mitochondrial assembly/function and oxidative phosphorylation, crucial for AML survival/proliferation and resistance to venetoclax, a potent BCL2 inhibitor and widely used first-line targeted therapy for AML in the clinic. Mechanistically, ALKBH1 catalyzes 5-formylcytosine at tRNA wobble positions, reprograming decoding and facilitating codon-biased translation, a mechanism we term “epitranslatomic Midas touch,” which in turn drives leukemogenesis and drug resistance by promoting the synthesis of key oncogenic proteins like WDR43. Targeting ALKBH1, particularly together with venetoclax, exhibited potent antileukemia efficacy in preclinical models with favorable safety profiles. Collectively, our findings elucidate ALKBH1’s pivotal role in codon-biased translation and tumorigenesis and propose a novel therapeutic strategy for cancer treatment. Significance: This study uncovers that ALKBH1-driven tRNA-decoding reprogramming and codon-biased translation, termed “epitranslatomic Midas touch,” is crucial for leukemogenesis, leukemia stem cell/leukemia-initiating cell self-renewal, mitochondria structure/function, and resistance to venetoclax. Targeting ALKBH1, especially in combination with venetoclax, offers a promising therapeutic strategy to combat drug resistance in AML and potentially other ALKBH1-overexpressing cancers.
- Open Access
- 1 November 2024
- Published by Tsinghua University Press in Food Science and Human Wellness
- Vol. 13 (6) , 3245-3255
The potential mechanism of Isodon suzhouensis against COVID-19 via EGFR/TLR4 pathways
Corona Virus Disease 2019 (COVID-19) has brought the new challenges to scientific research. Isodon suzhouensis has good anti-inflammatory and antioxidant stress effects, which is considered as a potential treatment for COVID-19. The possibility for the treatment of COVID-19 with suzhouensis and its potential mechanism of action were explored by employing molecular docking and network pharmacology. Network pharmacology and molecular docking were used to screen drug targets, and Lipopolysaccharide (LPS) induced RAW264.7 and NR8383 cells inflammation model was used for experimental verification. Collectively a total of 209 possible linkages against 18 chemical components from suzhouensis and 1194 COVID-19 related targets were selected. Among these, 164 common targets were obtained from the intersection of suzhouensis and COVID-19. GO and KEGG enriched 582 function targets and 87 target proteins pathways, respectively. The results from molecular docking studies revealed that rutin, vitexin, isoquercitrin and quercetin had significant binding ability with SARS-CoV-23CLpro and ACE2. In vitro studies showed that Isodon suzhouensis extract (ISE) may inhibit the activation of PI3K/Akt pathway and the expression level of downstream pro-inflammatory factors by inhibiting the activation of EGFR in RAW264.7 cells induced by LPS. In addition, ISE was able to inhibit the activation of TLR4/NF-κB signaling pathway in NR8383 cells exposed to LPS. Overall, the network pharmacology and in vitro studies conclude that active components from suzhouensis have strong therapeutic potential against COVID-19 through multi-target, multi-pathway dimensions and can be a promising candidate against COVID-19.
- 1 November 2024
- Published by Tsinghua University Press in Food Science and Human Wellness
- Vol. 13 (6) , 3245-3255
Open AccessThe potential mechanism of Isodon suzhouensis against COVID-19 via EGFR/TLR4 pathways
Corona Virus Disease 2019 (COVID-19) has brought the new challenges to scientific research. Isodon suzhouensis has good anti-inflammatory and antioxidant stress effects, which is considered as a potential treatment for COVID-19. The possibility for the treatment of COVID-19 with suzhouensis and its potential mechanism of action were explored by employing molecular docking and network pharmacology. Network pharmacology and molecular docking were used to screen drug targets, and Lipopolysaccharide (LPS) induced RAW264.7 and NR8383 cells inflammation model was used for experimental verification. Collectively a total of 209 possible linkages against 18 chemical components from suzhouensis and 1194 COVID-19 related targets were selected. Among these, 164 common targets were obtained from the intersection of suzhouensis and COVID-19. GO and KEGG enriched 582 function targets and 87 target proteins pathways, respectively. The results from molecular docking studies revealed that rutin, vitexin, isoquercitrin and quercetin had significant binding ability with SARS-CoV-23CLpro and ACE2. In vitro studies showed that Isodon suzhouensis extract (ISE) may inhibit the activation of PI3K/Akt pathway and the expression level of downstream pro-inflammatory factors by inhibiting the activation of EGFR in RAW264.7 cells induced by LPS. In addition, ISE was able to inhibit the activation of TLR4/NF-κB signaling pathway in NR8383 cells exposed to LPS. Overall, the network pharmacology and in vitro studies conclude that active components from suzhouensis have strong therapeutic potential against COVID-19 through multi-target, multi-pathway dimensions and can be a promising candidate against COVID-19.
- Open Access
- 23 February 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (8) , eadk3127
Therapeutic targeting Tudor domains in leukemia via CRISPR-Scan Assisted Drug Discovery
Epigenetic dysregulation has been reported in multiple cancers including leukemias. Nonetheless, the roles of the epigenetic reader Tudor domains in leukemia progression and therapy remain unexplored. Here, we conducted a Tudor domain–focused CRISPR screen and identified SGF29, a component of SAGA/ATAC acetyltransferase complexes, as a crucial factor for H3K9 acetylation, ribosomal gene expression, and leukemogenesis. To facilitate drug development, we integrated the CRISPR tiling scan with compound docking and molecular dynamics simulation, presenting a generally applicable strategy called CRISPR-Scan Assisted Drug Discovery (CRISPR-SADD). Using this approach, we identified a lead inhibitor that selectively targets SGF29’s Tudor domain and demonstrates efficacy against leukemia. Furthermore, we propose that the structural genetics approach used in our study can be widely applied to diverse fields for de novo drug discovery.
- 23 February 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (8) , eadk3127
Open AccessTherapeutic targeting Tudor domains in leukemia via CRISPR-Scan Assisted Drug Discovery
Epigenetic dysregulation has been reported in multiple cancers including leukemias. Nonetheless, the roles of the epigenetic reader Tudor domains in leukemia progression and therapy remain unexplored. Here, we conducted a Tudor domain–focused CRISPR screen and identified SGF29, a component of SAGA/ATAC acetyltransferase complexes, as a crucial factor for H3K9 acetylation, ribosomal gene expression, and leukemogenesis. To facilitate drug development, we integrated the CRISPR tiling scan with compound docking and molecular dynamics simulation, presenting a generally applicable strategy called CRISPR-Scan Assisted Drug Discovery (CRISPR-SADD). Using this approach, we identified a lead inhibitor that selectively targets SGF29’s Tudor domain and demonstrates efficacy against leukemia. Furthermore, we propose that the structural genetics approach used in our study can be widely applied to diverse fields for de novo drug discovery.
- Open Access
- 17 March 2022
- Published by Springer Nature in Cell Death & Differentiation
- Vol. 29 (9) , 1769-1789
A novel HIF-2α targeted inhibitor suppresses hypoxia-induced breast cancer stemness via SOD2-mtROS-PDI/GPR78-UPRER axis
Hypoxic tumor microenvironment (TME) plays critical roles in induction of cancer stem cell-like phenotype in breast cancer and contribute to chemoresistance. However, the mechanism underlying stemness reprogramming of breast cancer cells (BCs) by hypoxic TME remains largely unknown. In the present study, we illustrated that HIF-2α, but not HIF-1α, induces stemness in BCs under hypoxia through SOD2-mtROS-PDI/GRP78-UPRER pathway, linking mitochondrial metabolic state to endoplasmic reticulum (ER) response via mitochondrial reactive oxygen species (mtROS) level. HIF-2α activates endoplasmic reticulum unfolded protein response (UPRER) in drug-sensitive MCF7 and T47D cells to induce drug-resistant stem-like phenotype. Genetic depletion or pharmacological inhibition (YQ-0629) of HIF-2α abolished hypoxia-induced stem-like phenotype in vitro and in vivo. Mechanistically, HIF-2α activates transcription of superoxide dismutase 2 (SOD2) under hypoxia and thereby decreases mtROS level. With less mtROS transported to endoplasmic reticulum, the expression and activity of protein disulfide isomerase (PDI) is suppressed, allowing glucose-regulated protein 78 (GRP78) to dissociate from receptor proteins of UPRER and bind misfolded protein to activate UPRER, which eventually confer chemoresistance and stem-like properties to BCs. Moreover, the increase in mtROS and PDI levels caused by HIF-2α knockdown and the subsequent UPRER inhibition could be substantially rescued by mitoTEMPOL (a mtROS scavenger), 16F16 (a PDI inhibitor), or GRP78 overexpression. Overall, we reported the critical roles of HIF-2α-SOD2-mtROS-PDI/GRP78-UPRER axis in mediating hypoxia-induced stemness in BCs, highlighting the interaction between organelles and providing evidence for further development of targeted HIF-2α inhibitor as a promising therapeutic strategy for chemoresistant breast cancer.
- 17 March 2022
- Published by Springer Nature in Cell Death & Differentiation
- Vol. 29 (9) , 1769-1789
Open AccessA novel HIF-2α targeted inhibitor suppresses hypoxia-induced breast cancer stemness via SOD2-mtROS-PDI/GPR78-UPRER axis
Hypoxic tumor microenvironment (TME) plays critical roles in induction of cancer stem cell-like phenotype in breast cancer and contribute to chemoresistance. However, the mechanism underlying stemness reprogramming of breast cancer cells (BCs) by hypoxic TME remains largely unknown. In the present study, we illustrated that HIF-2α, but not HIF-1α, induces stemness in BCs under hypoxia through SOD2-mtROS-PDI/GRP78-UPRER pathway, linking mitochondrial metabolic state to endoplasmic reticulum (ER) response via mitochondrial reactive oxygen species (mtROS) level. HIF-2α activates endoplasmic reticulum unfolded protein response (UPRER) in drug-sensitive MCF7 and T47D cells to induce drug-resistant stem-like phenotype. Genetic depletion or pharmacological inhibition (YQ-0629) of HIF-2α abolished hypoxia-induced stem-like phenotype in vitro and in vivo. Mechanistically, HIF-2α activates transcription of superoxide dismutase 2 (SOD2) under hypoxia and thereby decreases mtROS level. With less mtROS transported to endoplasmic reticulum, the expression and activity of protein disulfide isomerase (PDI) is suppressed, allowing glucose-regulated protein 78 (GRP78) to dissociate from receptor proteins of UPRER and bind misfolded protein to activate UPRER, which eventually confer chemoresistance and stem-like properties to BCs. Moreover, the increase in mtROS and PDI levels caused by HIF-2α knockdown and the subsequent UPRER inhibition could be substantially rescued by mitoTEMPOL (a mtROS scavenger), 16F16 (a PDI inhibitor), or GRP78 overexpression. Overall, we reported the critical roles of HIF-2α-SOD2-mtROS-PDI/GRP78-UPRER axis in mediating hypoxia-induced stemness in BCs, highlighting the interaction between organelles and providing evidence for further development of targeted HIF-2α inhibitor as a promising therapeutic strategy for chemoresistant breast cancer.